A comparison of two methods for calculating total antipsychotic dose

Hong Kong Journal of Psychiatry

Volumn 17, Issue 3, 2007, Pages 87-90

  Hung, Gabriel B K ^a  

^a CASTLE PEAK HOSPITAL   (Hong Kong)

Author keywords

Antipsychotic agents; Chlorpromazine; Therapeutic equivalency

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIFLUOPERAZINE;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; HONG KONG; HUMAN; INTERMETHOD COMPARISON; MENTAL HEALTH SERVICE; PRESCRIPTION; PSYCHOSIS; RECOMMENDED DRUG DOSE;

EID: 36049039614     PISSN: 10262121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Royal College of Psychiatrists. Consensus statement on the use of high-dose antipsychotic medication. Council Report CR138. London: Royal College of Psychiatrists; 2006.
2. Davis JM. Dose equivalence of the antipsychotic drugs. J Psychiatr Res 1974;11:65-9.
3. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004;24:192-208.
4. Dewan M, Koss M. The clinical impact of reported variance in potency of antipsychotic agents. Acta Psychiatr Scand 1995;91:229-32.
5. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-7.
6. Yorston G, Pinney A. Chlorpromazine equivalents and percentage of British National Formulary maximum recommended dose in patients receiving high-dose antipsychotics. Psychiatr Bull R Coll Psychiatr 2000;24:130-2.
7. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary (51st edition). London: BMA & Royal Pharmaceutical Society of Great Britain; 2006.
8. Taylor D, Paton C, Kerwin R. The Maudsley 2005-2006 prescribing guidelines. London: Taylor & Francis; 2005.
9. Quality Assurance Sub-committee in Psychiatry. An audit on psychotropic drug use in schizophrenic inpatients. Hong Kong: Hospital Authority; 2004.
10. Harrington M, Lelliott P, Paton C, Okocha C, Duffett R, Sensky T. The results of a multi-centre audit of the prescribing of antipsychotic drugs for inpatients in the UK. Psychiatr Bull R Coll Psychiatr 2002;26:414-8.
11. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary (49th edition). London: BMA & Royal Pharmaceutical Society of Great Britain; 2005.
12. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002;106:323-30.
13. Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006;188:122-7.
14. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998;173:325-9.
15. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-6.